These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31919699)

  • 21. Direct conversion of human umbilical cord mesenchymal stem cells into dopaminergic neurons for Parkinson's disease treatment.
    Liu J; Ji Z; He Q; Chen H; Xu X; Mei Q; Hu Y; Zhang H
    Neurobiol Dis; 2024 Oct; 201():106683. PubMed ID: 39343249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating Parkinson's Disease with Human Bone Marrow Mesenchymal Stem Cell Secretome: A Translational Investigation Using Human Brain Organoids and Different Routes of In Vivo Administration.
    Mendes-Pinheiro B; Campos J; Marote A; Soares-Cunha C; Nickels SL; Monzel AS; Cibrão JR; Loureiro-Campos E; Serra SC; Barata-Antunes S; Duarte-Silva S; Pinto L; Schwamborn JC; Salgado AJ
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.
    Chen W; Huang Q; Ma S; Li M
    ACS Chem Neurosci; 2019 Feb; 10(2):839-851. PubMed ID: 30346716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease.
    Hoban DB; Howard L; Dowd E
    Neuroscience; 2015 Sep; 303():402-11. PubMed ID: 26166730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-dependent effect of mesenchymal stromal cells co-grafted with dopaminergic neurons in a Parkinson's disease rat model.
    Rodriguez-Pallares J; Garcia-Garrote M; Parga JA; Labandeira-Garcia JL
    J Cell Mol Med; 2021 Oct; 25(20):9884-9889. PubMed ID: 34535974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesenchymal stromal cell-derived secretome-based therapy for neurodegenerative diseases: overview of clinical trials.
    Ghasemi M; Roshandel E; Mohammadian M; Farhadihosseinabadi B; Akbarzadehlaleh P; Shamsasenjan K
    Stem Cell Res Ther; 2023 May; 14(1):122. PubMed ID: 37143147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From Transcriptome to Behavior: Intranasal Injection of Late Passage Human Olfactory Stem Cells Displays Potential in a Rat Model of Parkinson's Disease.
    Alizadeh R; Boroujeni ME; Kamrava SK; Tehrani AM; Bagher Z; Heidari F; Bluyssen HAR; Farhadi M
    ACS Chem Neurosci; 2021 Jun; 12(12):2209-2217. PubMed ID: 34048212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olfactory mucosa stem cells: An available candidate for the treatment of the Parkinson's disease.
    Simorgh S; Alizadeh R; Eftekharzadeh M; Haramshahi SMA; Milan PB; Doshmanziari M; Ramezanpour F; Gholipourmalekabadi M; Seifi M; Moradi F
    J Cell Physiol; 2019 Dec; 234(12):23763-23773. PubMed ID: 31173364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of Human Umbilical Cord Mesenchymal Stromal Cells in Protection of Dopaminergic Neurons from Apoptosis by Reducing Oxidative Stress in the Early Stage of a 6-OHDA-Induced Parkinson's Disease Model.
    Chi H; Guan Y; Li F; Chen Z
    Cell Transplant; 2019 Dec; 28(1_suppl):87S-99S. PubMed ID: 31775521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease.
    Levy YS; Bahat-Stroomza M; Barzilay R; Burshtein A; Bulvik S; Barhum Y; Panet H; Melamed E; Offen D
    Cytotherapy; 2008; 10(4):340-52. PubMed ID: 18574767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential therapy with dental tissue-derived mesenchymal stem cells in Parkinson's disease.
    Xiao Z; Lei T; Liu Y; Yang Y; Bi W; Du H
    Stem Cell Res Ther; 2021 Jan; 12(1):5. PubMed ID: 33407864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advancements in Autologous Stem Cell Transplantation for Parkinson's Disease.
    Shi JX; Zhang KZ
    Curr Stem Cell Res Ther; 2024; 19(10):1321-1327. PubMed ID: 37691194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stem cell treatment for Parkinson's disease: an update for 2005.
    Snyder BJ; Olanow CW
    Curr Opin Neurol; 2005 Aug; 18(4):376-85. PubMed ID: 16003112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells.
    Pantcheva P; Reyes S; Hoover J; Kaelber S; Borlongan CV
    Expert Rev Neurother; 2015 Oct; 15(10):1231-40. PubMed ID: 26394528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The future of cell-based transplantation therapies for neurodegenerative disorders.
    Lazic SE; Barker RA
    J Hematother Stem Cell Res; 2003 Dec; 12(6):635-42. PubMed ID: 14977473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson's disease.
    Chung TH; Hsu SC; Wu SH; Hsiao JK; Lin CP; Yao M; Huang DM
    Nanoscale; 2018 Feb; 10(6):2998-3007. PubMed ID: 29372743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action.
    Kim YJ; Park HJ; Lee G; Bang OY; Ahn YH; Joe E; Kim HO; Lee PH
    Glia; 2009 Jan; 57(1):13-23. PubMed ID: 18661552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unravelling the Parkinson's puzzle, from medications and surgery to stem cells and genes: a comprehensive review of current and future management strategies.
    Chandrababu K; Radhakrishnan V; Anjana AS; Rajan R; Sivan U; Krishnan S; Baby Chakrapani PS
    Exp Brain Res; 2024 Jan; 242(1):1-23. PubMed ID: 38015243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From regenerative strategies to pharmacological approaches: can we fine-tune treatment for Parkinson's disease?
    Silva RC; Domingues HS; Salgado AJ; Teixeira FG
    Neural Regen Res; 2022 May; 17(5):933-936. PubMed ID: 34558504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective effect of bone marrow-derived mesenchymal stem cell secretome in 6-OHDA-induced Parkinson's disease.
    Mahendru D; Jain A; Bansal S; Malik D; Dhir N; Sharma AR; Sarma P; Prakash A; Nahar U; Bhatia A; Bhattacharyya S; Medhi B
    Regen Med; 2021 Oct; 16(10):915-930. PubMed ID: 34553608
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.